Chementator Briefs
Ultrathin membrane Researchers led by professors Hideto Matsuyama and Tomohisa…
Focus on Sensors
Wireless transmitters save on level sensor installation Reduce the cost…

Comment Business & Economics

Catalent extends commercial spray-drying capacity in Europe

By Scott Jenkins |


Catalent, Inc. (Somerset, N.J.; www.catalent.com), a leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.

This agreement immediately extends Catalent’s global spray drying offering by making available to Catalent and Catalent’s customers the dedicated use of the existing Niro PSD2 and PSD4 spray driers at the facility. These spray dryers are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations as well as a secondary vacuum dryer. Catalent is now able to offer spray drying solutions from early-phase development through clinical supply and all the way to fully scaled-up commercial finished dose form manufacturing in Europe.

Under the terms of this agreement, Catalent will also have access to the facility’s integrated quality control and analytical capabilities with scientific support resources, enabling an end-to-end approach for customers.

“This agreement not only gives Catalent access to spray drying capabilities at Haverhill and its state-of-the-art equipment, but also an experienced and skilled team at the site with expertise in commercial-scale spray dried dispersions, which are frequently used today to overcome the solubility challenges with many new medicines,” said Jonathan Arnold, President of Catalent’s Oral Drug Delivery business unit.

Earlier this year, Catalent announced a $40M investment in its Winchester, Kentucky facility that includes adding commercial-scale spray drying with high-potent handling capabilities, as well as other increases to the site’s capacity and its formulation and controlled-release tablet and capsule manufacturing capabilities.

Niro is a registered trademark of GEA Group (www.gea.com)

Catalent is a leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. 

Related Content
Show Preview-Interphex 2019
Interphex 2019 will take place April 2–4 at the Jacob Javits Convention Center in New York City. Focused on biotechnology…
Interphex 2018 Show Preview
Interphex, the annual event focused on pharmaceutical and biotechnology manufacturing, takes place April 17–19 at the Jacobs Javits Center in…

Chemical Engineering publishes FREE eletters that bring our original content to our readers in an easily accessible email format about once a week.
Subscribe Now
Improving chemical production processes with IIoT and AI technologies
New filtration technology for highly corrosive media
PTA production: Lowering OPEX without compromising on quality
Sure that zero means zero in your zero-liquid discharge (ZLD) process?
How separation processes profit from Industrial Internet of Things (IIoT) solutions

View More

Live chat by BoldChat